Denver PWM LLC Makes New $94,000 Investment in Moderna, Inc. (NASDAQ:MRNA)

Denver PWM LLC acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 790 shares of the company’s stock, valued at approximately $94,000.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its stake in Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after buying an additional 5,129,800 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Moderna by 28.8% during the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after acquiring an additional 1,614,460 shares in the last quarter. Capital World Investors lifted its stake in Moderna by 0.5% during the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after purchasing an additional 18,728 shares during the last quarter. Norges Bank acquired a new position in Moderna in the fourth quarter valued at approximately $347,565,000. Finally, Mawer Investment Management Ltd. increased its stake in Moderna by 6.7% in the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after purchasing an additional 120,621 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent analyst reports. William Blair restated a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a research note on Wednesday, August 28th. The Goldman Sachs Group cut their target price on Moderna from $204.00 to $178.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. Oppenheimer boosted their target price on Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, June 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, August 1st. Ten research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $123.79.

Moderna Stock Performance

NASDAQ:MRNA opened at $73.44 on Friday. The firm has a market cap of $28.15 billion, a price-to-earnings ratio of -4.69 and a beta of 1.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The firm’s fifty day moving average price is $101.13 and its 200 day moving average price is $112.69.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($3.62) earnings per share. On average, sell-side analysts expect that Moderna, Inc. will post -9.52 EPS for the current year.

Insiders Place Their Bets

In other news, Director Noubar Afeyan sold 202,832 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the completion of the transaction, the director now directly owns 1,528,557 shares of the company’s stock, valued at approximately $226,746,145.38. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Noubar Afeyan sold 202,832 shares of the company’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the transaction, the director now directly owns 1,528,557 shares of the company’s stock, valued at approximately $226,746,145.38. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Shannon Thyme Klinger sold 5,178 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $148.09, for a total transaction of $766,810.02. Following the completion of the transaction, the insider now owns 15,947 shares of the company’s stock, valued at approximately $2,361,591.23. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 316,168 shares of company stock worth $44,094,621. Company insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.